Oct 29, 2019 Syros Presents New Preclinical Data on SY-5609, Its Highly Selective Oral CDK7 Inhibitor, at AACR-NCI-EORTC International Conference
Oct 24, 2019 Syros Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newly Diagnosed Unfit AML Patients
Aug 1, 2019 Syros Reports Second Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
